Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. cancer survival rates improving

  (This version of the Feb 19 story replaces paragraphs two, six and seven with new text to clarify that the statistics reflected the decline in risk of death from cancer, not an increase in survival.)   By Andrew M. Seaman (Reuters Health) – The proportion of people surviving years after a cancer diagnosis is […]

Read More »

Common asthma steroids linked to side effects in adrenal glands

<span class="articleLocation”>(Reuters Health) – After stopping steroids commonly prescribed for asthma and allergies, a significant number of people may experience signs of malfunctioning in the adrenal glands, a European study finds. So-called adrenal insufficiency can be dangerous, especially if the person’s body has to cope with a stress like surgery, injury or a serious illness, […]

Read More »

Ovary removal may improve breast cancer survival with gene mutation

<span class="articleLocation”>(Reuters Health) – Women with a gene mutation that puts them at a high risk of breast and ovarian cancers have better survival odds if their ovaries and fallopian tubes are removed soon after a breast cancer diagnosis, suggests a new study from Canada. Women with the BRCA1 gene mutation who were diagnosed with […]

Read More »

High morale linked to longer survival among elderly

A pensioner sits in a residential home for the elderly in Emmenbruecke near Lucerne December 7, 2007. Reuters/Christian Hartmann <span class="articleLocation”>(Reuters Health) – Whether it is cause or effect is unclear, but high morale seems to go along with a longer life, according to a new Scandinavian study. Among people 85 years and older, those […]

Read More »

Targazyme, Inc., Announces FDA Concurrence on Targazyme's Special Protocol Assessment for a Planned Phase 3 Registration Trial for the Treatment of Patients With Hematologic Malignancies

SAN DIEGO, CA–(Marketwired – April 23, 2015) – Targazyme, Inc., announced today that the U.S. Food and Drug Administration (FDA) and Targazyme have reached concurrence on the company’s Special Protocol Assessment (SPA) application for its Phase 3 registration trial. This pivotal trial is designed to evaluate the efficacy of TZ101-treated cells in patients with hematologic […]

Read More »

AstraZeneca, Juno latest to collaborate on immuno-oncology drugs

(Reuters) – A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body’s immune system to kill cancer cells. The partnership between AstraZeneca’s research and development arm MedImmune and Juno is the latest collaboration between companies intent on developing a new class of drugs known as […]

Read More »

Tisch MS Research Center Of New York Reports Early Improvement In Stem Cell Trial

NEW YORK, April 23, 2015 /PRNewswire/ — Tisch MS Research Center of New York (Tisch MSRCNY) today announced encouraging preliminary results from its FDA-approved Phase I trial using autologous neural stem cells in the treatment of multiple sclerosis (MS). MS is a chronic autoimmune disease of the central nervous system where the myelin sheath is attacked […]

Read More »

Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1450 in Staphylococcal Skin Infections

LAUSANNE, Switzerland, April 23, 2015 /PRNewswire/ — Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far. This study […]

Read More »

Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis

CORK, Ireland, April 23, 2015 /PRNewswire/ — Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), today announced results for its hepatitis C treatment simeprevir at The International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL) in Vienna. Late-breaking results from the Phase 3 […]

Read More »

Hyperemesis gravidarum tied to children’s neurological problems

A woman holds her stomach at the last stages of her pregnancy in Bordeaux April 28, 2010. Reuters/Regis Duvignau (Reuters Health) – Children born to women who suffered severe nausea and vomiting during pregnancy are more likely to be diagnosed with neurological developmental disorders, according to a small U.S. study. Compared to children of women […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom